We give you a written timeline estimate for your case before you commit.Get my quote
Is Komzifti available in Saudi Arabia? How families get Komzifti (ziftomenib)
A plain answer for families in Saudi Arabia, checked against FDA, manufacturer and regulator sources.
Reviewed by the Reserve Meds clinical operations team on 13 October 2026.
Is Komzifti available in Saudi Arabia?
Komzifti (ziftomenib) is an FDA-approved oral menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). As of 13 October 2026, we found no public record that Komzifti is registered by SFDA in Saudi Arabia. The legal route is a named-patient request: the treating hospital, on your specialist's request, asks the Saudi Food and Drug Authority (SFDA) for permission to import Komzifti for one patient, using the US FDA approval as the reference. Once approved, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy. We do not prescribe. We give you a written timeline estimate for your case before you commit.
- Registration in Saudi Arabia: not found in public sources as of 13 October 2026. Your hospital confirms before filing.
- Legal route: Named-patient import request to SFDA, filed by the treating hospital.
- Who applies: a licensed Saudi hospital, on the written request of your treating consultant.
- We give you a written timeline estimate for your case before you commit.
- Price: Every case gets a written custom quote before you commit.
What Komzifti is
Komzifti (ziftomenib) is made by Kura Oncology. The US FDA approved it on 13 November 2025 for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. It is given as 600 mg by mouth once a day.
In the KOMET-001 trial, 23% of patients reached complete remission or complete remission with partial blood count recovery. Warnings include differentiation syndrome, heart rhythm (QTc) changes, and harm to an unborn baby.
We found no approval outside the United States in public sources as of 13 October 2026.
The legal route in Saudi Arabia
Because Komzifti is approved by the US FDA, a licensed Saudi hospital can ask SFDA for permission to import it for one named patient. This is often called the named-patient route.
SFDA expects the medicine to be registered with at least one reference regulator, such as the US FDA or the European Medicines Agency. The hospital signs a declaration that it takes responsibility for safe use. A licensed importer signs a declaration covering quality during transport. The patient or a legal guardian gives written consent after the treating doctor explains the benefits and risks.
A different route, SFDA's Special Access Program, is for medicines that have no reference approval anywhere, such as products still in clinical trials. It is run through SFDA's clinical trials department and usually starts with the drug's sponsor. Komzifti does not need that route because it already has FDA approval.
We did not find it in the SFDA public drugs list when we checked on 17 October 2026, so ask your hospital pharmacy to confirm the status in SFDA's system before anything is filed.
Who does what
- Your treating specialist decides whether Komzifti is right for the patient and writes the letter and prescription.
- The hospital files the request and is responsible for giving the medicine safely.
- The Saudi Food and Drug Authority (SFDA) decides whether to approve an import of an unregistered medicine.
- Kura Oncology makes Komzifti and decides where it can be supplied.
- Reserve Meds coordinates the paperwork, the US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents the hospital will usually need
- A letter from the treating specialist: diagnosis, past treatments, and why Komzifti is needed
- A prescription with the dose and how long treatment should last
- Supporting reports, such as pathology, genetic or laboratory results
- The hospital's request form and its signed declaration of responsibility
- Written consent from the patient or a legal guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
Timeline, step by step
- Doctor's letter. Your specialist writes the clinical letter and prescription.
- Hospital request. The hospital pharmacy files the named-patient request with SFDA.
- Regulator decision. SFDA reviews the request and issues an approval or asks for more information.
- US sourcing. Our US-licensed wholesale partner supplies the medicine, and it is shipped with the right temperature controls.
- Hospital receipt. The medicine is received at the hospital pharmacy, which gives it to the patient.
The overall time is our planning estimate, not a promise. The regulator and the manufacturer set their own timelines.
What Komzifti costs
Your total cost depends on the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. We do not prescribe, and we do not decide what the regulator approves.
Ask about Komzifti in Saudi Arabia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is Komzifti approved in Saudi Arabia?
As of 13 October 2026, we found no public record that Komzifti is registered by SFDA in Saudi Arabia. We found no approval outside the United States in public sources as of 13 October 2026. We did not find it in the SFDA public drugs list when we checked on 17 October 2026, so ask your hospital pharmacy to confirm the status in SFDA's system before anything is filed.
Who applies for permission to use Komzifti in Saudi Arabia?
The treating hospital applies to the Saudi Food and Drug Authority (SFDA), on the written request of your specialist. Families do not apply on their own, and Reserve Meds does not apply for you.
How long does it take to get Komzifti in Saudi Arabia?
We give you a written timeline estimate for your case before you commit. The regulator's review time and shipping can change this.
How much does Komzifti cost?
Your total cost, including shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Can Reserve Meds send Komzifti straight to our home?
No. Komzifti goes to the hospital pharmacy named in the regulator's approval, which then gives it to the patient. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy.
Sources
Checked on 13 October 2026. Regulator rules change. Your hospital pharmacy confirms the current procedure before filing.
- The ASCO Post: FDA approves ziftomenib for NPM1-mutated AML, 13 Nov 2025
- Targeted Oncology: FDA approves ziftomenib in NPM1-mutant AML (KOMET-001 results)
- PharmaKnowl: Named Patient Program in Saudi Arabia (reference regulators, hospital and importer declarations, patient consent)
- SFDA: Special Access Program (SAP) guidance, version 1.0
- Saudi Food and Drug Authority (SFDA)